Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-5b777bbd6c-rbv74 Total loading time: 0 Render date: 2025-06-23T01:39:51.901Z Has data issue: false hasContentIssue false

Chapter 5 - The Safety of Phytocannabinoids and Cannabinoids in Clinical Practice

from Section 1 - An Introduction to Cannabinoid Science

Published online by Cambridge University Press:  12 October 2020

Steven James
Steven James
Affiliation:
University of California, San Diego
Get access

Summary

The clinician should be aware that marijuana and medical marijuana are currently recognized by the US Drug Enforcement Agency (DEA) Comprehensive Drug Abuse Prevention and Control Act of 1970 (Controlled Substances Act) as a Schedule I controlled substance are defined as having a high potential for abuse, no currently accepted medicinal use in treatment in the United States, and a lack of accepted safety data for use of the treatment under medical supervision (Drug Enforcement Administration, 2016).

Type
Chapter
Information
A Clinician's Guide to Cannabinoid Science , pp. 55 - 69
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Allsop, D. J. et al. (2014) ‘Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial’, JAMA Psychiatry, 71(3), 281–291. doi:10.1001/jamapsychiatry.2013.3947.Google Scholar
Andréasson, S. et al. (1987) ‘Cannabis and schizophrenia. A longitudinal study of Swedish conscripts’, The Lancet, 330(8574), 1483–1486. doi:10.1016/S0140-6736(87)92620-1.Google Scholar
Anthony, J. C., Warner, L. A. and Kessler, R. C. (1997) ‘Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey.’, in Marlatt, G. A. and VandenBos, G. R. (eds.), Addictive Behaviors: Readings on Etiology, Prevention, and Treatment. Washington: American Psychological Association, pp. 3–39. doi:10.1037/10248-001.Google Scholar
Arseneault, L. et al. (2004) ‘Causal association between cannabis and psychosis: examination of the evidence’, British Journal of Psychiatry, 184(2), 110–117. doi:10.1192/bjp.184.2.110.Google Scholar
Campbell, V. A. (2001) ‘Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation’, Neuropharmacology, 40(5), 702–709. doi:10.1016/S0028-3908(00)00210-0.Google Scholar
Chait, L. D. and Zacny, J. P. (1992) ‘Reinforcing and subjective effects of oral Δ9-THC and smoked marijuana in humans’, Psychopharmacology, 107(2–3), 255–262. doi:10.1007/BF02245145.Google Scholar
Chen, J. et al. (1990) ‘Δ9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis’, Psychopharmacology, 102(2), 156–162. doi:10.1007/BF02245916.CrossRefGoogle ScholarPubMed
Chiarlone, A. et al. (2014) ‘A restricted population of CB1 cannabinoid receptors with neuroprotective activity’, Proceedings of the National Academy of Sciences of the United States of America, 111(22), 8257–8262. doi:10.1073/pnas.1400988111.Google Scholar
Compton, D. R., Dewey, W. L. and Martin, B. R. (1990) ‘Cannabis dependence and tolerance production’, Advances in Alcohol and Substance Abuse, 9(1–2), 129–147. doi:10.1080/J251v09n01_08.CrossRefGoogle ScholarPubMed
Cooper, Z. D. et al. (2013) ‘A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers’, Addiction Biology, 18(6), 993–1002. doi:10.1111/j.1369-1600.2012.00461.x.CrossRefGoogle ScholarPubMed
Dalton, W. S. et al. (1976) ‘Influence of cannabidiol on delta-9-tetrahydrocannabinol effects’, Clinical Pharmacology & Therapeutics, 19(3), 300–309. doi:10.1002/cpt1976193300.CrossRefGoogle ScholarPubMed
Di Chiara, G. and Imperato, A. (1988) ‘Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats’, Proceedings of the National Academy of Sciences of the United States of America, 85(14), 5274–5278. doi:10.1073/pnas.85.14.5274.Google Scholar
Diana, M. et al. (1998) ‘Mesolimbic dopaminergic decline after cannabinoid withdrawal’, Proceedings of the National Academy of Sciences of the United States of America, 95(17), 10269–10273. doi:10.1073/pnas.95.17.10269.Google Scholar
Downer, E. J. and Campbell, V. A. (2010) ‘Phytocannabinoids, CNS cells and development: a dead issue?’, Drug and Alcohol Review, 29(1), 91–98. doi:10.1111/j.1465-3362.2009.00102.x.Google Scholar
Drug Enforcement Administration (2016). Title 21 United States Code (USC) Controlled Substances Act. Available at: www.deadiversion.usdoj.gov/21cfr/21usc/812.htm (Accessed: May 26, 2020).Google Scholar
D’Souza, D.C. et al. (2004) ‘The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis’, Neuropsychopharmacology, 29, 1558–1572. doi:10.1038/sj.npp.1300496.Google Scholar
Gardner, E. (2014) ‘Cannabinoids and addiction’, in Pertwee, R, (ed)., Handbook of Cannabis. Oxford: Oxford University Press, pp. 173–188.Google Scholar
Georgotas, A. and Zeidenberg, P. (1979) ‘Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior’, Comprehensive Psychiatry, 20(5), 427–432. doi:10.1016/0010-440X(79)90027-0.CrossRefGoogle Scholar
Gorelick, D. A. et al. (2013) ‘Tolerance to effects of high-dose oral Δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers’, Journal of Analytical Toxicology, 37(1), 11–16. doi:10.1093/jat/bks081.Google Scholar
Greenwich Biosciences (2018) Epidiolex® (cannabidiol). Carlsbad, CA: Greenwich Biosciences, Inc. Available at: www.epidiolexhcp.com/themes/custom/epidiolex_hcp/files/factsheet.pdf (Accessed: May 30, 2020).Google Scholar
Hall, K. E. et al. (2018) ‘Mental health-related emergency department visits associated with cannabis in Colorado’, Academic Emergency Medicine, 25(5), 526–537. doi:10.1111/acem.13393.CrossRefGoogle ScholarPubMed
Hampson, A. J. et al. (1998) ‘Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants’, Proceedings of the National Academy of Sciences of the United States of America, 95(14), 8268–8273. https://doi.org/10.1073/pnas.95.14.8268.Google Scholar
Haney, M. (2005) ‘The marijuana withdrawal syndrome: diagnosis and treatment’, Current Psychiatry Reports, 7(5), 360–366. doi:10.1007/s11920-005-0036-1.CrossRefGoogle ScholarPubMed
Haney, M. et al. (1997) ‘Factors influencing marijuana self-administration by humans’, Behavioural Pharmacology, 8(2–3), 101–112.Google ScholarPubMed
Haney, M. et al. (1999) ‘Abstinence symptoms following oral THC administration to humans’, Psychopharmacology, 141(4), 385–394. doi:10.1007/s002130050848.Google Scholar
Haney, M. et al. (2013) ‘Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse’, Neuropsychopharmacology, 38(8), 1557–1565. doi:10.1038/npp.2013.54.CrossRefGoogle Scholar
Haney, M. et al. (2016) ‘Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis’, Neuropsychopharmacology, 41(8), 1974–1982. doi:10.1038/npp.2015.367.CrossRefGoogle ScholarPubMed
Hayakawa, K. et al. (2007) ‘Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance’, Neuropharmacology, 52(4), 1079–1087. doi:10.1016/j.neuropharm.2006.11.005.Google Scholar
Hoffman, D. et al. (1975) ‘On the carcinogenicity of marijuana smoke’, in Runekles, V. C. (ed.), Recent Advances in Phytochemistry. New York: Plenum Press. pp. 63–81.Google Scholar
Jones, R. T., Benowitz, N. and Bachman, J. (1976) ‘Clinical studies of cannabis tolerance and dependence’, Annals of the New York Academy of Sciences, 282(1), 221–239. doi:10.1111/j.1749-6632.1976.tb49901.x.Google Scholar
Justinova, Z. et al. (2004) ‘The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys’, Psychopharmacology, 173(1), 186–194. doi:10.1007/s00213-003-1693-6.Google Scholar
Jutras-Aswad, D. et al. (2009) ‘Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome’, European Archives of Psychiatry and Clinical Neuroscience, 259(7), 395–412. doi:10.1007/s00406-009-0027-z.Google Scholar
Lankenau, S. E. et al. (2018) ‘Health conditions and motivations for marijuana use among adult medical marijuana patients and non-patient marijuana users’, Drug and Alcohol Review, 37(2), 237–246. doi:10.1111/dar.12534.Google Scholar
Large, M. et al. (2011) ‘Cannabis use and earlier onset of psychosis: a systematic meta-analysis’, Archives of General Psychiatry, 68(6), 555–561.Google Scholar
Levin, F. R. et al. (2011) ‘Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial’, Drug and Alcohol Dependence, 116(1–3), 142–150. doi:10.1016/drugalcdep.2010.12.010.Google Scholar
McKinney, D. L. et al. (2008) ‘Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to Δ9-tetrahydrocannabinol’, Journal of Pharmacology and Experimental Therapeutics, 324(2), 664–673. doi:10.1124/jpet.107.130328.Google Scholar
Montanari, L. et al. (2017) ‘Cannabis use among people entering drug treatment in Europe: a growing phenomenon?’, European Addiction Research, 23(3), 113–121. doi:10.1159/000475810.Google Scholar
Monte, A. A., Zane, R. D. and Heard, K. J. (2015) ‘The implications of marijuana legalization in Colorado’, JAMA: Journal of the American Medical Association, 313(3), 241–242. doi:10.1001/jama.2014.17057.Google Scholar
Moore, T. H. et al. (2007) ‘Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review’, Lancet, 370(9584), 319–328. doi:10.1016/S0140-6736(07)61162-3.CrossRefGoogle ScholarPubMed
National Institute on Drug Abuse (2019) Monitoring the Future Survey: High School and Youth Trends, Revised December 2019. Available at www.drugabuse.gov/publications/drugfacts/monitoring-future-survey-high-school-youth-trends (Accessed: June 8, 2020).Google Scholar
Piomelli, D. et al. (2018) ‘Cannabis and the opioid crisis’, Cannabis and Cannabinoid Research, 3(1), 108–116. doi:10.1089/can.2018.29011.rtl.CrossRefGoogle ScholarPubMed
Sachs, J., McGlade, E. and Yurgelun-Todd, D. (2015) ‘Safety and toxicology of cannabinoids’, Neurotherapeutics, 12(4), 735–746. doi:10.1007/s13311-015-0380-8.Google Scholar
Schierenbeck, T. et al. (2008) ‘Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana’, Sleep Medicine Reviews, 12(5), 381–389. doi:10.1016/j.smrv.2007.12.004.Google Scholar
Serpell, M. G., Notcutt, W. and Collin, C. (2013) ‘Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis’, Journal of Neurology, 260(1), 285–295. doi:10.1007/s00415-012-6634-z.Google Scholar
Solowij, N. et al. (2011) ‘Does cannabis cause lasting brain damage?’ in Castle, D, Murray, R. M and D’Souza, D. C. (eds.), Marijuana and Madness, 2nd ed. Cambridge: Cambridge University Press, pp. 103–113. doi:10.1017/CBO9780511706080.010.Google Scholar
Stephens, R. S., Roffman, R. A. and Curtin, L. (2000) ‘Comparison of extended versus brief treatments for marijuana use’, Journal of Consulting and Clinical Psychology, 68(5), 898–908. doi:10.1037/0022-006X.68.5.898.Google Scholar
Tanda, G., Pontieri, F. E. and Di Chiara, G. (1997) ‘Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism’, Science, 276(5321), 2048–2050. doi:10.1126/science.276.5321.2048.Google Scholar
Trigo, J. M. et al. (2016) ‘Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings’, Drug and Alcohol Dependence, 161, 298–306. doi:10.1016/j.drugalcdep.2016.02.020.CrossRefGoogle ScholarPubMed
US Food and Drug Administration (2019). ‘Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing May 31, 2019’. Available at: www.fda.gov/news-events/fda-meetings-conferences-and-workshops/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds (Accessed: May 27, 2020).Google Scholar
US Food and Drug Administration (2020). FDA and Cannabis: Research and Drug Approval Process. Available at: www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process (Accessed: May 26, 2020).Google Scholar
van Os, J. et al. (2002) ‘Cannabis use and psychosis: a longitudinal population-based study’, American Journal of Epidemiology, 156(4), 319–327. doi:10.1093/aje/kwf043.Google Scholar
Villares, J. (2007) ‘Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain’, Neuroscience, 145(1), 323–334. doi:10.1016/j.neuroscience.2006.11.012.Google Scholar
Wang, G. S. et al. (2018) ‘Marijuana and acute health care contacts in Colorado’, Preventive Medicine, 104, 24–30. doi:10.1016/j.ypmed.2017.03.022.Marijuana.Google Scholar
Wikler, A. (1976) ‘Aspects of tolerance to and dependence on cannabis’, Annals of the New York Academy of Sciences, 282(1), 126–147. doi:10.1111/j.1749-6632.1976.tb49893.x.Google Scholar
Yücel, M. et al. (2008) ‘Regional brain abnormalities associated with long-term heavy cannabis use’, Archives of General Psychiatry, 65(6), 694–701. doi:10.1001/archpsyc.65.6.694.Google Scholar
Zammit, S. et al. (2002) ‘Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study’, British Medical Journal, 325(7374), 1199–1201. doi:10.1136/bmj.325.7374.1199.CrossRefGoogle ScholarPubMed
Zammit, S. et al. (2008) ‘Effects of cannabis use on outcomes of psychotic disorders: systematic review’, British Journal of Psychiatry, 193(5), 357–363. doi:10.1192/bjp.bp.107.046375.CrossRefGoogle ScholarPubMed
Zuardi, A. W. et al. (1982) ‘Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects’, Psychopharmacology, 76(3), 245–250.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×